By Katherine Hamilton
Immutep said a treatment it is developing showed strong results in overall survival among head and neck cancer patients.
The Australian cancer-treatment company said Monday the median rate for overall survival was 17.6 months for patients taking a combination of eftilagimod alfa and Merck's pembrolizumab drug Keytruda.
Shares rose 8% to $1.85 in premarket trading Monday.
The drug combination is designed to treat people with recurrent or metastatic head and neck squamous cell carcinoma. Combining the therapies has increased response rates by sevenfold and more than doubled median overall survival compared with historical results. The treatment has no new safety signals, Immutep said.
Immutep has requested a meeting with the Food and Drug Administration to discuss next steps including paths to approval. The company is continuing patient follow-ups, data collection and analysis, and plans to provide a further update later this year.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
May 05, 2025 09:05 ET (13:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.